platoseedplatoseed
Replacing organ transplant with an infusion
Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.
HepaTx is developing off-the-shelf stem cell–based therapies for late-stage liver disease as an alternative to liver transplant, aiming to make liver regeneration clinically and economically practical. The company emphasizes regenerative medicine approaches and scalable manufacturing to treat patients with end-stage liver failure.
HepaTx leverages regenerative medicine technologies to create stem cell–based therapies for liver disease. The product concept centers on off-the-shelf cell therapies designed to regenerate liver tissue, with a scalable manufacturing process to enable practical clinical use as an alternative to organ transplantation.
Who it’s for: Hospitals and liver transplant centers, specialty clinics treating end-stage liver disease, biopharma/biotech partners focused on regenerative medicine
funding/investor associations mentioned; recognition as Impact Company of the Year (2022) by DotCom Magazine
New therapeutics to rejuvenate tissue and treat age-related diseases
Bioengineered kidneys for patients with kidney failure
